Gyre Therapeutics, Inc.

GYRE Healthcare Biotechnology

In the quarter to June 2026, revenue fell 2.12%, EPS was flat and free cash flow fell 130.5%, each against the same quarter a year earlier.

6.08 0.32 −5.00%
Market cap
$678.6M
P/E
0.0×
Fwd P/E
−21.7×
Dividend yield
—
F-score
4/9
Altman Z
16.83
Beneish M
−2.02
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

106.57 141.20 0.00 0.00
P/S ratio
6.15 5.41 5.44 5.70
P/FCF ratio
450.03 0.00 207.39 0.00
P/Operating CF
47.60 (112.14) 200.15 (39.65)
P/B ratio
4.93 10.59 4.65 4.65
Price to Tangible BV
5.11 11.51 4.81 4.81
EV/Sales
5.65 4.66 5.06 5.10
EV/EBITDA
62.60 38.79 235.25 0.00
EV/Operating CF
160.67 537.99 137.05 (120.29)
EV/FCF
413.62 (615.37) 192.86 (83.33)
Quick Ratio
5.41 5.21 3.68 3.59
Current Ratio
6.19 6.28 4.64 4.26
Net Debt/EBITDA
(8.28) (17.74) 5.74 5.80
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.77 0.68 0.80 0.66
Operating CF/Net income
3.94 (7.37) (0.37) 1.43
Capex/Depreciation
(1.86) (0.19) (0.26) (0.87)
Interest Coverage
— — — (15.23)
Research and Development Expense of Revenue
7.73% (0.32%) 29.92% 65.75%
Selling, General and Administrative Expense of Revenue
64.28% 81.99% 94.84% 74.29%
Intangible Assets out of Total Assets
0.03 0.02 0.03 0.02
Share Based Compensation of Revenue
2.02% 13.43% 11.47% 7.13%
Graham Net Nets
0.11 0.19 0.10 0.13
Graham Number
1.54 0.87 0.00 0.00
Earnings Yield
0.94% 0.71% (1.15%) (3.03%)
Free Cash Flow Yield
0.22% (0.14%) 0.48% (1.07%)
Revenue per Share
0.34 0.38 0.25 0.29
Operating CF per Share
0.16 (0.06) 0.03 (0.17)
Capex per Share
(0.01) 0.00 0.00 (0.01)
Free Cash Flow per Share
0.15 (0.06) 0.03 (0.18)
Cash per Share
0.66 1.04 0.55 0.74
Shareholders Equity per Share
1.51 2.11 1.50 1.64
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
1.51 2.11 1.50 1.64
Free Cash Flow
13.63 (5.75) 3.00 (18.01)
Working Capital
82.66 125.58 71.94 93.41
Capital Expenditures
(0.60) (0.13) (0.18) (1.28)
Net Current Asset Value
76.61 117.96 66.70 87.74
EV/EBIT
81.69 47.30 0.00 0.00
Capex to Sales
0.02 0.00 0.01 0.04
Price to Operating Income
88.88 54.91 0.00 0.00
Other line items
Average Receivables
23.44 28.04 21.69 26.44
Average Payables
0.43 0.72 0.19 0.65
Average Inventory
7.62 8.25 9.62 10.14
Average Assets
142.31 172.58 145.90 175.95
Average Common Equity
117.94 78.97 120.64 135.97

Fold the line items

Columns are period end dates